Vice Chairman of the Executive Committee and Chief Scientific Officer,Johnson & Johnson. “We have a proven track record in partnering with others to develop and deliver antiviral therapies that serve the needs of diverse populations worldwide. While ...
Johnson & Johnson (NYSE: JNJ) announced today that 25 abstracts featuring robust research to understand unmet needs in generalized myasthenia gravis (gMG) and evaluate nipocalimab as a potential advanced treatment option will be...
Partnering with us Partnering-with-usQuick access Policies, disclosures and position statements Product quality certificates Partnering with us Speak Up line Code of Ethics Get in touch Find a product - enquire Media enquiries Investor enquiries Search JM jobs and apply Location and ...
Deloitte, a tax and advisory organization, is partnering with Johnson & Johnson on the launch of Illustrate Change, focusing on building momentum around representation in medical illustrations and reduce health disparities among people of color. Featuring the work of Nigerian medical illustrator Chidieber...
“To serve the healthcare needs of people everywhere, we need diverse perspectives and viewpoints," says Ashley McEvoy, Worldwide Chairman, Medical Devices, Johnson & Johnson and Executive Sponsor of the Open&Out employee resource group for LGBTQ+ employ
Johnson & Johnson's 45 advertising, marketing, design and digital agencies, plus projects and agency relationship insights.
MarketWatch Automation Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. ...
but I think our team really did an extraordinary job last year of partnering with healthcare systems and physicians and patients to make sure that they could get on and stay on the therapies that they need. So our outlook for the rest of the year really remains strong for our sector regar...
Earlier this week, Johnson & Johnson announced it had paused “further dosing in all our COVID-19 vaccine candidate clinical trials” due to an “unexplained illness” in a volunteer. One day later, drugmaker Eli Lilly paused its clinical trial for an an